Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B

• Status: Recruiting
• Trial end date: 2025-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taichung Veterans General Hospital
• Treatments: Entecavir; Tenofovir

Criteria

Inclusion Criteria:

1. Patients more than 20 years old

2. Chronic hepatitis B patients

3. Patients who were indicated for hepatitis B virus antiviral therapy

Exclusion Criteria:

1. Decompensated liver disease (Child-Pugh B &C)

2. End stage renal disease (eGRF < 15 ml/min/1.73m2)

3. Prior use of nucleot(s)ide analogues for chronic hepatitis B

4. Prior use of interferon for chronic hepatitis B within six months

5. Known history of human immunodeficiency virus or hepatitis C virus co-infection

6. Concurrent other uncontrolled malignancy

7. Women in pregnancy or lactation

8. Cannot conform to the study protocol of this study